---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-332736"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2026-08-04T20:02:18+00:00"
generated_at: "2026-08-04T20:05:02.414041+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Syndax Q2 2026 revenue $72.8M; Revuforj net revenue $54.7M (+91% YoY); Niktimvo $60.3M (+67%)

## Summary
- Total revenue $72.8M (Revuforj $54.7M, Niktimvo collaboration $18.1M); H1 2026 net loss $49.4M vs $71.8M prior year.
- Cash $575.1M; expects profitability; full-year 2026 R&D+SG&A ~$400M excl. $50M stock comp.
- Pipeline expanded: SNDX-4321 (allosteric EGFR inhibitor for NSCLC) IND by end 2026; SNDX-62122 (menin inhibitor for MF) IND in 2027.
- Topline data expected in 4Q26 from Phase 2 trials of axatilimab in IPF and frontline cGVHD.
- Revuforj prescriptions ~1,500 in Q2 (+121% YoY); average treatment duration increasing.

## SEC filing metadata
- accession: 0001193125-26-332736
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2026-08-04T20:02:18+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000119312526332736/0001193125-26-332736-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000119312526332736/sndx-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-332736
- JSON: https://secwatch.observer/filing/0001193125-26-332736.json
- Plain text: https://secwatch.observer/filing/0001193125-26-332736.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.